InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
6
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-3.7%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by OMSTEAD DANIEL R, Président. Director active across 2 companies, notably Tekla Life Sciences Investors. In total, 6 reports have been published. Breakdown: 6 buys · 0 sell. Total volume traded: €779k. History available since 11 August 2021. The latest transaction was filed on 25 September 2023 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations6 total
9,500 shares@ US$15.633249.8% of flowShares of Beneficial InterestSEC:0001104659-23-103574:0
Ideal exit: 21 Jun 2024 (T+270)
10,096 shares@ US$12.392623.8% of flowShares of Beneficial InterestSEC:0001104659-23-103576:0
Ideal exit: 21 Jun 2024 (T+270)
9,500 shares@ US$15.876750.2% of flowShares of Beneficial InterestSEC:0001104659-23-102458:0
Ideal exit: 16 Jun 2024 (T+270)
12,000 shares@ US$12.683828.8% of flowShares of Beneficial InterestSEC:0001104659-23-102460:0
Ideal exit: 16 Jun 2024 (T+270)
6,403 shares@ US$21.6323.7% of flowShares of Beneficial InterestSEC:0001104659-21-103959
Ideal exit: 8 May 2022 (T+270)
6,403 shares@ US$21.630.026% mcap50.0% of flowShares of Beneficial InterestSEC:0001104659-21-103959:0
Ideal exit: 8 May 2022 (T+270)
6 of 6 declarations
About OMSTEAD DANIEL R
Daniel R. Omstead is the President of Tekla Life Sciences Investors. He is responsible for managing and directing investments in the life sciences sector. His investment expertise is essential for maximizing the performance of Tekla's portfolio.
